Brand-Blinding Needed In Comparison Studies, WaterWipes Told In Review Of Baby Wipe Claim
Firm Qualifies '#1 Clinically Proven' Claim After NAD Review On Kimberly-Clark Challenge
NAD says firm's superiority and establishment claims should be removed from marketing. WaterWipes relied on results from “Baby Skin Integrity Comparison Survey” published in Journal of Pediatrics and Neonatology, but NAD agreed with challenger Kimberly-Clark that not blinding the brands from study subjects weakened the results.
You may also be interested in...
FDA Encourages Voluntary Device Shortage Reporting After PHE End
The FDA updated its policies regarding 506J notifications for device manufacturers at the end of the public health emergency.
Digital Health Roundup: HIMSS, Cardio Conversations, ChatGPT And New FDA Guidances
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses how two medtech CEOs are and aren’t using ChatGPT in their businesses while Reed Miller talks about his “Cardio Conversations” podcast interviews with Quentin Blackford, CEO of iRhythm, and Rob Krummen, CEO of Vektor Medical. Washington, DC-based reporter Hannah Daniel reviews highlights from the HIMSS conference and the latest updates on FDA guidances.
FDA, CDER Discuss AI/ML In Drug Development In Discussion Papers
FDA hopes to engage in “mutual learning” with stakeholders to develop new regulations for the use of AI/ML drug development.